- In a 5-year follow-up of the response-adapted SWOG S0816 study in patients with newly diagnosed (ND) advanced-stage Hodgkin lymphoma (HL), negative positron emission tomography 2 (PET2) demonstrated low predictive value for PFS.
Why this matters
- SWOG S0816 was the first study of its kind to be published in this setting.
- Results of SWOG S0816 at a median follow-up of 5.9 (range, 0.2-8.3) years in 331 patients with ND advanced-stage HL with evaluable PET2.
- All patients had received 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD).
- Patients who achieved complete response (CR) at PET2 (Deauville score ≤3) received 4 more cycles of ABVD; others received 6 cycles of escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (eBEACOPP).
- Funding: NIH; National Cancer Institute; National Clinical Trials Network.
- 5-year estimated PFS:
- 24% of PET2-negative patients experienced a progression event; thus, 5-year PFS was 76% (95% CI, 70%-81%).
- In PET2-positive patients: 5-year PFS was 66% (95% CI, 52%-76%).
- 14% of eBEACOPP-treated patients experienced a second primary malignancy vs 2% with ABVD (P=.001).
- 5-year OS was 94% (95% CI, 91%-96%).
- Retrospective data.